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Abstract: While recent increases in our understanding of the biology of neuroblastoma have allowed
for more precise risk stratification and improved outcomes for many patients, children with high-risk
neuroblastoma continue to suffer from frequent disease relapse, and despite recent advances
in our understanding of neuroblastoma pathogenesis, the outcomes for children with relapsed
neuroblastoma remain poor. These children with relapsed neuroblastoma, therefore, continue
to need novel treatment strategies based on a better understanding of neuroblastoma biology to
improve outcomes. The discovery of new tumor targets and the development of novel antibody- and
cell-mediated immunotherapy agents have led to a large number of clinical trials for children with
relapsed neuroblastoma, and additional clinical trials using molecular and genetic tumor profiling
to target tumor-specific aberrations are ongoing. Combinations of these new therapeutic modalities
with current treatment regimens will likely be needed to improve the outcomes of children with
relapsed and refractory neuroblastoma.
Keywords: neuroblastoma; relapsed neuroblastoma; recurrent neuroblastoma; refractory neuroblastoma;
personalized treatment; ALK; RET; MIBG; retinoic acid
1. Introduction
With new treatment strategies, including immunotherapy and therapies directed against
tumor-specific molecular aberrations, the outcomes of children with high-risk neuroblastoma have
significantly improved over the past two decades. Despite these recent successes, however, many
of these children continue to suffer from refractory or relapsed disease, and to date, there are no
established curative treatment options for many of these patients. Relapsed neuroblastoma has been
considered invariably fatal in the past [1], with a median overall survival time for patients with
refractory neuroblastoma of only 27.9 months and with an overall survival of only 11.0 months for
patients with relapsed disease [2]. However, the reported 5-year overall survival rate for children after
the initial relapse of neuroblastoma is 20% [3,4]. These outcomes were dependent on both the time of
relapse and the initial patient tumor stage [3–5], suggesting that a subset of patients with recurrent
neuroblastoma can be cured with appropriate treatment and also emphasizing the need for additional
treatment options for these patients.
Recent data presented by Modak and colleagues and Manole and colleagues indicate that patients
with isolated local recurrence can be treated successfully with surgical tumor resection and/or radiation
therapy at sites of active disease [6,7]. These authors further recommend using chemotherapy regimens
with demonstrated activity in children with recurrent neuroblastoma, rather than experimental therapy
for localized relapses. However, children with neuroblastoma who suffer disease relapse often develop
metastatic tumors resistant to standard therapies, and the underlying molecular profiles and signaling
pathway activity in these relapsed tumors are likely significantly different from those in untreated
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tumors due to novel molecular and genetic aberrations induced or selected by prior therapy [8,9].
The goals of treatment in these patients historically have not been curative, but rather to prolong
survival and minimize the toxicities of additional therapy. However, recent data have suggested
that more aggressive treatment of these patients to achieve a complete or nearly complete response,
followed by additional consolidation or maintenance therapy, can lead to durable disease remission and
even cure [10], suggesting that the goals of treatment for many children with relapsed and refractory
neuroblastoma may need to be modified.
2. Systemic Chemotherapy and Radiotherapy
2.1. Systemic Chemotherapy
Initial treatment regimens for patients with relapsed or refractory neuroblastoma typically include
chemotherapy combinations distinct from those previously used. Topotecan and irinotecan have
both demonstrated activity as single agents in preclinical and clinical studies of neuroblastoma via
inhibition of the topoisomerase I enzyme [11–16] and are both commonly used for the treatment of
children with relapsed neuroblastoma. An early phase II study using a combination of topotecan
and cyclophosphamide in children with relapsed neuroblastoma demonstrated objective responses
in 6 of 13 patients [17]. A follow-up study demonstrated that children with recurrent neuroblastoma
who were treated with the combination of cyclophosphamide and topotecan had increased response
rates compared to those who received topotecan as a single agent, although no difference in overall
survival rates was observed in treated patients [18,19]. Using a combination of higher doses of
cyclophosphamide and topotecan with vincristine, children with primary refractory neuroblastoma
had an overall response rate of 19%, while the response rate was 52% for those with their initial
neuroblastoma relapse [20]. A phase II study of topotecan combined with doxorubicin and vincristine
(TVD) demonstrated a 64% overall response rate in 25 patients with relapsed neuroblastoma, with
4 patients having complete responses to the TVD combination [21]. The TVD regimen was subsequently
incorporated into the SIOPEN HR-NBL-1 treatment protocol for high-risk neuroblastoma as salvage
therapy for refractory patients with insufficient responses to induction therapy. Following two courses
of TVD, 4 of 63 patients (6.4%) enrolled on this protocol had an overall complete response (CR), while
28 of 63 (44.4%) had a partial response (PR). Of note, 23 patients achieved sufficient response to be
eligible to receive myeloablative therapy with stem cell rescue [22]. However, the long-term benefits of
TVD in these patients will likely need to be established in further clinical trials.
Combinations of irinotecan with the alkylating agent temozolomide have also demonstrated
efficacy in children with relapsed neuroblastoma. A single-institution study reported 2 complete
responses to the combination of irinotecan and temozolomide among 19 patients with refractory
disease, with 7 patients with mixed responses and 10 with stable disease (SD) [23]. Children
with relapsed neuroblastoma treated on a separate multi-institutional study using lower doses of
irinotecan and temozolomide had an overall response rate of 15%, while an additional 53% had
SD [24]. Subsequent clinical trials have attempted to improve on these results with the addition of
bevacizumab [25] and temsirolimus [26] to the irinotecan/temozolomide combination. Although these
combinations were well tolerated by patients, the additional agents unfortunately did not significantly
improve patient outcomes. A subsequent phase I study utilized irinotecan alone combined with
the proteasome inhibitor bortezomib, and 2 of 17 evaluable children with refractory or relapsed
neuroblastoma demonstrated responses (including one CR), and another 4 children had prolonged
stable disease [27], suggesting that this combination might prove more effective in children with
relapsed neuroblastoma and should be tested in further studies.
Combinations of ifosfamide, carboplatin, and etoposide (ICE) have also been routinely employed
for children with relapsed neuroblastoma. In a single institution study, ICE was well tolerated and
led to disease regression in 14 of 17 patients (82%) who were treated after their first neuroblastoma
relapse. Disease regression was also seen in 13 of 26 patients (50%) with refractory neuroblastoma
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and in 12 of 34 patients (35%) who developed progressive disease during frontline treatment [28].
In a separate study, 37% of patients with relapsed or refractory neuroblastoma responded to the
ICE regimen, while an additional 17% had SD [29]. Additionally, 15 of 16 children with high-risk
neuroblastoma receiving ICE for upfront treatment had either partial or complete responses [30],
further demonstrating the efficacy of ifosfamide-based chemotherapy regimens for both frontline
treatment of high-risk neuroblastoma and for initial treatment of patients with relapsed neuroblastoma.
Prior studies have also suggested that some patients with relapsed or refractory neuroblastoma
might benefit from more aggressive treatment consisting of myeloablative chemotherapy followed
by autologous stem cell rescue (ASCR). One recent study demonstrated that children with relapsed
neuroblastoma who received myeloablative therapy followed by ASCR had improved survival rates
compared to those who received chemotherapy alone (43.5% vs. 9.6%), with 7 of 23 patients achieving
either CR or PR after ASCR. However, 2 of the 23 patients experienced transplant-related mortality,
suggesting that further studies to identify which patients would receive the most benefit from this
approach are needed [31]. Additional studies have suggested that haploidentical stem cell transplantation
may also be beneficial for children with relapsed and refractory neuroblastoma, with 5-year event-free
survival (EFS) and overall survival (OS) rates of 19% and 23%, respectively, and no treatment-related
mortality [32]. However, patients with residual disease who underwent these transplants had significantly
worse outcomes than those in complete remission, and a large number of patients experienced acute or
chronic graft-versus-host disease (GVHD), suggesting that further study is required.
2.2. Radiotherapy
Additional forms of therapy for children with relapsed and refractory neuroblastoma have
directly targeted markers expressed on the surfaces of neuroblastoma tumor cells. The vast majority of
neuroblastoma tumors demonstrate tumor cell surface expression of the norepinephrine transporter
(NET), suggesting that the use of benzylguanidine analogues, such as meta-iodobenzylguanidine
(MIBG), that bind to this transporter would selectively target these neuroblastoma tumor cells [33].
Approximately 90% of children with neuroblastoma have tumors that are detectable by radiolabeled
MIBG imaging, and infusion of radiolabeled MIBG, therefore, allows for targeted delivery of radiation
therapy directly to sites of active disease. Initial studies of 131I-MIBG used therapeutically in
children with recurrent neuroblastoma showed overall response rates of 21–47% [34–36]. Although
useful disease palliation and responses were seen in approximately one-third of patients, clinical
benefit was often only temporary [37]. Subsequent studies used MIBG treatment followed by ASCR,
as dose escalation was often associated with significant hematopoietic toxicity, particularly in heavily
pretreated patients [38]. In a large multi-institutional phase II study, 36% of children with either
relapsed or refractory neuroblastoma who were treated with increasing doses of 131I-MIBG had
either complete or partial responses, while another 34% of patients demonstrated stable disease
with a median time to progression of 6 months [39]. A subsequent retrospective analysis of
218 patients treated with 131I-MIBG therapy at a single institution demonstrated a 27% overall
response rate. However, 24% of relapsed patients had progressive disease compared to only 9%
of refractory patients, and 39% of relapsed patients had stable disease compared to 59% of refractory
patients [40], suggesting patients with refractory neuroblastoma are most likely to benefit from
131I-MIBG therapy. The efficacy of 131I-MIBG therapy against neuroblastoma has led to subsequent
clinical trials incorporating 131I-MIBG therapy as a component of frontline treatment for children with
high-risk neuroblastoma, and ongoing clinical trials through the New Approaches to Neuroblastoma
Therapy (NANT) consortium are evaluating the efficacy of additional anticancer agents combined with
131I-MIBG therapy (NCT02035137) in children with relapsed and refractory neuroblastoma. Despite
the established efficacy of 131I-MIBG therapy in children with relapsed neuroblastoma, however, only
a limited number of institutions have the resources to support the administration of radioactive iodine
to pediatric patients, and the limited availability and accompanying need for available stem cells for
ASCR remain major challenges to the more widespread use of 131I-MIBG therapy.
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Prior studies have also shown that 77–89% of neuroblastoma cells express the somatostatin
receptor (SSTR) [41–43], suggesting that agents targeting the SSTR may also be effective for
neuroblastoma therapy. In adults with neuroendocrine tumors (NETs), peptide receptor radionuclide
therapy (PRRT) with high-activity 111In-, 177Lu-, and 90Y-labeled somatostatin analogues has been
successfully used [44,45]. In a single-institution study of PRRT, four children with relapsed
neuroblastoma received 17 cycles of palliative PRRT using either 111In-DOTATATE, 177Lu-DOTATATE,
or 90Y-DOTATATE. All four had objective responses, with two long-term survivors [46], supporting
ongoing clinical trials.
3. Molecularly Targeted Therapy
While regimens incorporating chemotherapy and radiotherapy with 131I-MIBG have
demonstrated efficacy in the treatment of children with relapsed and refractory neuroblastoma,
treatment options for children who suffer from subsequent disease relapses and progression remain
limited. However, ongoing investigations exploring the molecular mechanisms underlying the etiology
and pathogenesis of neuroblastoma have identified a number of novel therapeutic targets, and several
novel targeted agents have been shown to be highly active in preclinical models of neuroblastoma.
Many of these agents have been tested or are currently being evaluated in early phase clinical trials for
children with relapsed and refractory neuroblastoma (Table 1). Although untreated neuroblastoma
tumors have a relative paucity of mutations in therapeutically relevant gene targets [47,48], relapsed
neuroblastoma tumors have been found to have a number of actionable mutations [8,9], and initial
clinical trials employing therapies selected based on genomic alterations identified in individual
patient tumors have demonstrated both feasibility and efficacy, suggesting that molecularly targeted
therapy and individualized treatment may lead to increased rates of response and improved outcomes
for children with relapsed and refractory neuroblastoma.
3.1. Anaplastic Lymphoma Kinase (ALK)
Early efforts to identify gene mutations and other genetic aberrations in neuroblastoma tumors
that could serve as therapeutic targets focused on familial neuroblastoma, which accounts for
approximately 2% of all patients with neuroblastoma. Initial efforts determined that the majority
of these cases are associated with activating germline mutations in the anaplastic lymphoma kinase
(ALK) gene [49–52], and subsequent studies identified ALK gene mutations or gene amplifications
in up to 15% of sporadic high-risk neuroblastoma tumors [49,53]. High-risk neuroblastoma tumors
were also found to have increased ALK gene expression when compared to low-risk tumors [54],
further suggesting a potential role for ALK inhibitors in neuroblastoma therapy. In a subsequent
phase I trial, 79 children were enrolled and treated with the ALK inhibitor crizotinib, including
34 with neuroblastoma, 11 of which had known ALK mutations [55]. Despite an objective tumor
response rate of 67% in children with other tumors with ALK mutations, only 1 of 11 children with
neuroblastoma with ALK mutations (9%) demonstrated an objective response, suggesting that ALK
inhibitors will likely need to be combined with other therapies for maximal benefit. Initial studies
have identified synergistic combinations of ALK inhibitors with mTOR inhibitors [56] and with
CDK4/6 inhibitors [57], and these combinations may serve to overcome some of the limitations
of single-agent ALK inhibitor treatment for neuroblastoma. Additionally, novel second-generation
ALK inhibitors, such as lorlatinib (PF06463922), ceritinib (LDK378), and ensartinib, that are effective
against the crizotinib-resistant ALKF1174L mutant [58,59] are currently being evaluated in clinical trials
for children with neuroblastoma (NCT01742286, NCT03107988, NCT03213652), with early results
showing responses to ceritinib in six of nine patients with anaplastic large cell lymphoma (ALCL) and
myofibroblastic tumors with ALK gene aberrations. To date, one patient with relapsed neuroblastoma
with an ALKF1174L mutation had shrinkage of a retroperitoneal mass but concurrently experienced
central nervous system (CNS) disease progression [60], suggesting that higher doses may be required
to achieve adequate levels in neuroblastoma sanctuary sites such as the CNS.
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Table 1. Current open clinical trials for refractory and relapsed neuroblastoma.
NCT Number Title Drug Molecular Target TherapeuticClass
Study
Enrollment
Target
Eligibility
Age Range
Primary Site/Group
or Sponsor Status
NCT00089245
Radiolabeled Monoclonal Antibody Therapy
in Treating Patients with Refractory,
Recurrent, or Advanced CNS or
Leptomeningeal Cancer
Intrathecal 131I-8H9 B7-H3
Systemic
Radiotherapy 120 any
New York, NY
(Memorial Sloan
Kettering Cancer
Center)
Active,
recruiting
NCT00107289
Iodine 131I Metaiodobenzylguanidine in
Treating Patients with Recurrent, Progressive,
or Refractory Neuroblastoma or Malignant
Pheochromocytoma or Paraganglioma
131I-MIBG NET
Systemic
Radiotherapy 80 over 1 year
New York, NY
(Memorial Sloan
Kettering Cancer
Center)
Active,
recruiting
NCT00601003 Study of Nifurtimox to Treat Refractory orRelapsed Neuroblastoma or Medulloblastoma
Nifurtimox,
cyclophosphamide,
topotecan
Reactive Oxygen
Species
Systemic
Chemotherapy 100 up to 21 years
Beat Childhood
Cancer (BCC)
Active,
recruiting
NCT00638898
Busulfan, Melphalan, Topotecan
Hydrochloride, and a Stem Cell Transplant in
Treating Patients with Newly Diagnosed or
Relapsed Solid Tumor
Busulfan, melphalan,
topotecan N/A
Systemic
Chemotherapy 25
6 months to
40 years
Duarte, CA (City of
Hope Cancer Center)
Active, not
recruiting
NCT00788125
Dasatinib, Ifosfamide, Carboplatin, and
Etoposide in Treating Young Patients with
Metastatic or Recurrent Malignant
Solid Tumors
Carboplatin, dasatinib,
etoposide, ifosfamide
Multiple Kinases
(Abl, Src, c-Kit,
PDGFRβ)
Molecularly
Targeted
Therapy
143 1–25 years Duarte, CA (City ofHope Cancer Center)
Active, not
recruiting
NCT00877110
Anti-GD2 3F8 Antibody and Allogeneic
Natural Killer Cells for High-Risk
Neuroblastoma
Cyclophosphamide,
vincristine, topotecan,
NK cells, 3F8
GD2
Systemic
Chemotherapy
plus
Immunotherapy
71 any
New York, NY
(Memorial Sloan
Kettering Cancer
Center)
Active, not
recruiting
NCT00911560
Bivalent Vaccine with Escalating Doses of the
Immunological Adjuvant OPT-821, in
Combination with Oral β-glucan for
High-Risk Neuroblastoma
Adjuvant OPT-821 in a
vaccine containing two
antigens (GD2L and GD3L)
covalently linked to KLH
GD2L, GD3L Immunotherapy 215 up to 21 years
New York, NY
(Memorial Sloan
Kettering Cancer
Center)
Active,
recruiting
NCT01183884
3F8/GM-CSF Immunotherapy Plus
13-Cis-Retinoic Acid for Consolidation of
Second or Greater Remission of High-Risk
Neuroblastoma
3F8, GM-CSF, isotretinoin GD2 Immunotherapy 63 over18 months
New York, NY
(Memorial Sloan
Kettering Cancer
Center)
Active, not
recruiting
NCT01183897
3F8/GM-CSF Immunotherapy Plus
13-Cis-Retinoic Acid for Primary Refractory
Neuroblastoma in Bone Marrow
3F8, GM-CSF, isotretinoin GD2 Immunotherapy 31 over18 months
New York, NY
(Memorial Sloan
Kettering Cancer
Center)
Active, not
recruiting
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Table 1. Cont.
NCT Number Title Drug Molecular Target TherapeuticClass
Study
Enrollment
Target
Eligibility
Age Range
Primary Site/Group
or Sponsor Status
NCT01331135 Aflac ST0901 CHOANOME—Sirolimus inSolid Tumors (Aflac ST0901) Sirolimus mTOR
Molecularly
Targeted
Therapy
24 up to 30 years
Atlanta, GA
(Children’s
Healthcare of Atlanta)
Active, not
recruiting
NCT01419834
Humanized 3F8 Monoclonal Antibody
(Hu3F8) in Patients with High-Risk
Neuroblastoma and GD2-Positive Tumors
Hu3F8 GD2 Immunotherapy 74 over 2 years
New York, NY
(Memorial Sloan
Kettering Cancer
Center)
Active,
recruiting
NCT01467986
Multimodal Molecular Targeted Therapy to
Treat Relapsed or Refractory High-Risk
Neuroblastoma
Dasatinib, sirolimus,
irinotecan, temozolomide
Multiple Kinases
(Abl, Src, c-Kit,
PDGFRβ), mTOR
Molecularly
Targeted
Therapy
114 up to 25 years
Regensburg,
Germany (University
Hospital Regensburg)
Active,
recruiting
NCT01492673
Cyclophosphamide, Topotecan, and
Bevacizumab (CTB) in Patients with
Relapsed/Refractory Ewing’s Sarcoma and
Neuroblastoma
Cyclophosphamide,
topotecan, bevacizumab Angiogenesis
Molecularly
Targeted
Therapy
9 up to 21 years
New York, NY
(Memorial Sloan
Kettering Cancer
Center)
Active, not
recruiting
NCT01576692
Combination Chemotherapy, Monoclonal
Antibody, and Natural Killer Cells in Treating
Young Patients with Recurrent or Refractory
Neuroblastoma
Cyclophosphamide,
topotecan, Hu14.18K322A,
cisplatin, etoposide,
doxorubicin, Vincristine,
busulfan, melphalan,
natural killer cells,
GM-CSF, interleukin-2
GD2
Systemic
Chemotherapy
plus
Immunotherapy
34 up to 21 years
Memphis, TN (St.
Jude Children’s
Research Hospital)
Active, not
recruiting
NCT01601535 Study of MLN8237 in Combination withIrinotecan and Temozolomide
Alisertib (MLN8237),
irinotecan, temozolomide Aurora A Kinase
Molecularly
Targeted
Therapy
4 1–30 years
New Approaches to
Neuroblastoma
Therapy (NANT)
Active, not
recruiting
NCT01606878
Crizotinib and Combination Chemotherapy
in Treating Younger Patients with Relapsed or
Refractory Solid Tumors or Anaplastic Large
Cell Lymphoma
Crizotinib,
cyclophosphamide,
topotecan, vincristine,
doxorubicin
ALK, c-Met
Systemic
Chemotherapy
plus
Molecularly
Guided Therapy
65 1–21 years Children’s OncologyGroup
Active, not
recruiting
NCT01625351
A Study of CD45RA+ Depleted
Haploidentical Stem Cell Transplantation in
Children with Relapsed or Refractory Solid
Tumors and Lymphomas
Alemtuzumab, fludarabine,
sirolimus, busulfan,
melphalan
mTOR
Systemic
Chemotherapy
plus
Immunotherapy
23 2–21 years
Memphis, TN
(St. Jude Children’s
Research Hospital)
Active, not
recruiting
NCT01662804
Humanized 3F8 Monoclonal Antibody
(Hu3F8) When Combined with Interleukin-2
in Patients with High-Risk Neuroblastoma
and GD2-positive Solid Tumors
Hu3F8, IL-2 GD2 Immunotherapy 14 over 13months
New York, NY
(Memorial Sloan
Kettering Cancer
Center)
Active, not
recruiting
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Table 1. Cont.
NCT Number Title Drug Molecular Target TherapeuticClass
Study
Enrollment
Target
Eligibility
Age Range
Primary Site/Group
or Sponsor Status
NCT01711554
Lenalidomide and Dinutuximab With or
Without Isotretinoin in Treating Younger
Patients with Refractory or Recurrent
Neuroblastoma
Lenalidomide,
dinutuximab, isotretinoin GD2 Immunotherapy 62 up to 21 years
New Approaches to
Neuroblastoma
Therapy (NANT)
Active,
recruiting
NCT01742286
Phase I Study of LDK378 in Pediatric,
Malignancies with a Genetic Alteration in
Anaplastic Lymphoma Kinase (ALK)
Ceritinib (LDK378) ALK MolecularlyGuided Therapy 83 1–17 years
Novartis
Pharmaceuticals
Active, not
recruiting
NCT01757626
Combination Therapy of Antibody Hu3F8
With Granulocyte- Macrophage Colony
Stimulating Factor (GM-CSF) in Patients with
Relapsed/Refractory High-Risk
Neuroblastoma
Hu3F8 with GM-CSF GD2 Immunotherapy 224 any
New York, NY
(Memorial Sloan
Kettering Cancer
Center)
Active,
recruiting
NCT01804634
A Phase II Trial of Reduced Intensity
Conditioning and Haploidentical BMT for
High-risk Solid Tumors
Cyclophosphamide,
fludarabine, XRT N/A
Systemic
Chemotherapy
plus
Immunotherapy
20 up to 40 years
Baltimore, MD
(Sidney Kimmel
Cancer Center at
Johns Hopkins)
Active,
recruiting
NCT01956669
A Phase II Study of Pazopanib GW786034,
NSC# 737754 in Children, Adolescents, and
Young Adults with Refractory Solid Tumors
Pazopanib
Multiple Kinases
(VEGFR-1,
VEGFR-2,
VEGFR-3,
PDGFRβ, c-kit)
Molecularly
Targeted
Therapy
154 1–18 years Children’s OncologyGroup
Active,
recruiting
NCT02013336 Phase 1 Study of MM-398 PlusCyclophosphamide in Pediatric Solid Tumors
MM-398 (Irinotecan
sucrosofate liposomes),
cyclophosphamide
N/A Systemicchemotherapy 30 1–20 years
South Plains
Oncology
Consortium
Active,
recruiting
NCT02030964
N2012-01: Phase 1 Study of
Difluoromethylornithine (DFMO) and
Celecoxib with
Cyclophosphamide/Topotecan (DFMO)
DFMO, celecoxib,
cyclophosphamide,
topotecan
ODC
Molecularly
Targeted
Therapy
30 2–30 years
New Approaches to
Neuroblastoma
Therapy (NANT)
Active, not
recruiting
NCT02034981
Phase 2 Study Assessing Efficacy and Safety
of Crizotinib in Patients Harboring an
Alteration on ALK, MET or ROS1
Crizotinib ALK, c-Met MolecularlyGuided Therapy 246 over 1 year
Villejuif, France
(Institut Gustave
Roussy)
Active, not
recruiting
NCT02035137
131I-MIBG Alone VS. 131I-MIBG With
Vincristine and Irinotecan VS. 131I-MIBG
With Vorinostat (N2011-01)
131I-MIBG, vorinostat,
vincristine/irinotecan
NET
Systemic
radiotherapy
plus
Chemotherapy
105 2–30 years
New Approaches to
Neuroblastoma
Therapy (NANT)
Active,
recruiting
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Table 1. Cont.
NCT Number Title Drug Molecular Target TherapeuticClass
Study
Enrollment
Target
Eligibility
Age Range
Primary Site/Group
or Sponsor Status
NCT02076906 MR-guided High Intensity FocusedUltrasound (HIFU) on Pediatric Solid Tumors MR-HIFU N/A N/A 14 up to 30 years
Washington, DC
(Children’s National
Medical Center)
Active,
recruiting
NCT02095132
WEE1 Inhibitor MK-1775 and Irinotecan
Hydrochloride in Treating Younger Patients
with Relapsed or Refractory Solid Tumors
Irinotecan, AZD1775
(adavosertib) Wee1
Molecularly
Targeted
Therapy
154 2–21 years Children’s OncologyGroup
Active,
recruiting
NCT02100891
Phase 2 STIR Trial: Haploidentical Transplant
and Donor Natural Killer Cells for Solid
Tumors (STIR)
NK cells N/A Immunotherapy 20 any
Milwaukee, WI
(Medical College of
Wisconsin)
Active,
recruiting
NCT02124772
Study to Investigate Safety, Pharmacokinetic
(PK), Pharmacodynamic (PD) and Clinical
Activity of Trametinib in Subjects with Cancer
or Plexiform Neurofibromas and Trametinib
in Combination with Dabrafenib in Subjects
with Cancers Harboring V600 Mutations
Trametinib, dabrafenib MEK MolecularlyGuided Therapy 142 1–17 years
Novartis
Pharmaceuticals
Active,
recruiting
NCT02139397
Study of DFMO in Combination with
Bortezomib for Relapsed or Refractory
Neuroblastoma
DFMO, bortezomib ODC, Proteasome
Molecularly
Targeted
Therapy
38 up to 21 years Beat ChildhoodCancer (BCC)
Active,
recruiting
NCT02162732 Molecular-Guided Therapy for ChildhoodCancer
Precision
Medicine
Molecularly
Guided Therapy 200
13 months to
21 years
Beat Childhood
Cancer (BCC)
Active,
recruiting
NCT02163356
Fenretinide Lym-X-Sorb + Ketoconazole +
Vincristine for Recurrent or Resistant
Neuroblastoma (SPOC2013-001)
Fenretinide, ketoconazole,
vincristine N/A
Systemic
Chemotherapy 42 up to 30 years
South Plains
Oncology
Consortium
Active,
recruiting
NCT02169609 Safety Study of Dinutuximab Combined withImmunotherapy to Treat Neuroblastoma
Dinutuximab, GM-CSF,
isotretinoin, IL-2 GD2 Immunotherapy 25 any
Barcelona, Spain
(Hospital Sant Joan
de Deu)
Active, not
recruiting
NCT02173093
Activated T Cells Armed with GD2 Bispecific
Antibody in Children and Young Adults with
Neuroblastoma and Osteosarcoma
IL-2, GD2Bi-aATC,
GM-CSF GD2 Immunotherapy 40
13 months to
29 years
Detroit, MI
(Children’s Hospital
of Michigan)
Active,
recruiting
NCT02298348
Sorafenib and Cyclophosphamide/Topotecan
in Patients with Relapsed and Refractory
Neuroblastoma (N2013-02)
Sorafenib,
cyclophosphamide,
topotecan
Multiple Kinases
(Raf, VEGFR-2,
VEGFR-3, c-Kit)
Molecularly
Targeted
Therapy
18 up to 30 years
New Approaches to
Neuroblastoma
Therapy (NANT)
Active, not
recruiting
NCT02304458
Nivolumab With or Without Ipilimumab in
Treating Younger Patients with Recurrent or
Refractory Solid Tumors or Sarcomas
Ipilimumab, nivolumab PD-1, CTLA-4 Immunotherapy 484 1–30 years Children’s OncologyGroup
Active,
recruiting
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Table 1. Cont.
NCT Number Title Drug Molecular Target TherapeuticClass
Study
Enrollment
Target
Eligibility
Age Range
Primary Site/Group
or Sponsor Status
NCT02308527
Activity Study of Bevacizumab with
Temozolomide ± Irinotecan for
Neuroblastoma in Children
Bevacizumab,
temozolomide, irinotecan,
topotecan
Angiogenesis
Molecularly
Targeted
Therapy
160 1–21 years Cancer Research UK Active,recruiting
NCT02311621 Engineered Neuroblastoma CellularImmunotherapy (ENCIT)-01 Anti-CD171 CAR-T cells CD171 Immunotherapy 40
18 months to
26 years
Seattle, WA (Seattle
Children’s Hospital)
Active,
recruiting
NCT02332668
A Study of Pembrolizumab (MK-3475) in
Pediatric Participants with an Advanced Solid
Tumor or Lymphoma
(MK-3475-051/KEYNOTE-051)
Pembrolizumab PD-1 Immunotherapy 310 6 months to17 years
Merck Sharp &
Dohme Corp.
Active,
recruiting
NCT02343718
Vinblastine and Temsirolimus in Pediatric
Patients with Recurrent or Refractory
Lymphoma or Solid Tumours Including CNS
Tumours
Temsirolimus, vinblastine mTOR
Molecularly
Targeted
Therapy
7 1–18 years
Toronto, ON
(Hospital for Sick
Children)
Active, not
recruiting
NCT02378428 MIBG Therapy for Patients with MIBG AvidTumors (MIBG)
131I-MIBG NET
Systemic
Radiotherapy 65 1–40 years
Columbus, OH
(Nationwide
Children’s Hospital)
Active,
recruiting
NCT02390843
Simvastatin with Topotecan and
Cyclophosphamide in Relapsed and/or
Refractory Pediatric Solid and CNS Tumors
(AflacST1402)
Simvastatin,
cyclophosphamide,
topotecan
HMG-coA
Reductase
Systemic
Chemotherapy 36 1–29 years
Atlanta, GA
(Children’s
Healthcare of Atlanta)
Active,
recruiting
NCT02441088 Theranostics: 68GaDOTATOC and90YDOTATOC (PRRT)
90Y-DOTA-tyr3-Octreotide
(90Y-DOTATOC)
SSTR SystemicRadiotherapy 25 over 6 months
Iowa City, IA
(University of Iowa)
Active, not
recruiting
NCT02452554
Lorvotuzumab Mertansine in Treating
Younger Patients with Relapsed or Refractory
Wilms Tumor, Rhabdomyosarcoma,
Neuroblastoma, Pleuropulmonary Blastoma,
Malignant Peripheral Nerve Sheath Tumor, or
Synovial Sarcoma
Lorvotuzumab mertansine
(IMGN-901) CD56 Immunotherapy 114 1–30 years
Children’s Oncology
Group
Active, not
recruiting
NCT02508038 TCRαβ+/CD19+ Depleted HaploidenticalHSCT + Zoledronate
Zoledronate,
TCRαβ+/CD19+ depleted
Haploidentical HSCT
N/A Immunotherapy 21 7 months to21 years
Madison, WI
(University of
Wisconsin)
Active,
recruiting
NCT02520713 The iCat2, GAIN (Genomic AssessmentInforms Novel Therapy) Consortium Study
Precision
Medicine
Molecularly
Guided Therapy 825 up to 30 years
Boston, MA
(Dana-Farber Cancer
Institute)
Active,
recruiting
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Table 1. Cont.
NCT Number Title Drug Molecular Target TherapeuticClass
Study
Enrollment
Target
Eligibility
Age Range
Primary Site/Group
or Sponsor Status
NCT02536183
A Phase I Study of Lyso-thermosensitive
Liposomal Doxorubicin and MR-HIFU for
Pediatric Refractory Solid Tumors
MR-HIFU hyperthermia +
lyso-thermosensitive
liposomal doxorubicin
N/A SystemicChemotherapy 34 up to 30 years
Washington, DC
(Children’s National
Medical Center)
Active,
recruiting
NCT02541604
A Study to Evaluate the Safety, Tolerability,
Pharmacokinetics, Immunogenicity, and
Preliminary Efficacy of Atezolizumab
(Anti-Programmed Death-Ligand 1 [PD-L1]
Antibody) in Pediatric and Young Adult
Participants with Solid Tumors
Atezolizumab PD-L1 Immunotherapy 90 up to 30 years Hoffmann-La Roche Active, notrecruiting
NCT02557854
HIFU Hyperthermia with Liposomal
Doxorubicin (DOXIL) for Relapsed or
Refractory Pediatric and Young Adult Solid
Tumors
Doxil + MR-HIFU
Hyperthermia N/A
Systemic
Chemotherapy 14 1–40 years
Dallas, TX (University
of Texas
Southwestern
Medical Center)
Active,
recruiting
NCT02573896 Immunotherapy of Relapsed RefractoryNeuroblastoma with Expanded NK Cells
NK cells, dinutuximab,
lenalidomide GD2 Immunotherapy 24
1 month to
30 years
New Approaches to
Neuroblastoma
Therapy (NANT)
Active, not
yet
recruiting
NCT02574728
Sirolimus in Combination with Metronomic
Chemotherapy in Children with Recurrent
and/or Refractory Solid and CNS Tumors
Sirolimus, celecoxib,
etoposide,
cyclophosphamide
mTOR
Molecularly
Targeted
Therapy
60 1–30 years
Atlanta, GA
(Children’s
Healthcare of Atlanta)
Active,
recruiting
NCT02624388 Study of Genistein in Pediatric OncologyPatients (UVA-Gen001) (UVA-Gen001) Genistein N/A
Systemic
Chemotherapy 50 1–21 years
Charlottesville, VA
(University of
Virginia)
Active,
recruiting
NCT02630043 Trial of Tolcapone With Oxaliplatin forNeuroblastoma Tolcapone, oxaliplatin N/A
Systemic
Chemotherapy 21 up to 21 years
Beat Childhood
Cancer (BCC)
Active,
recruiting
NCT02638428 Genomics-Based Target Therapy for Childrenwith Relapsed or Refractory Malignancy
Ifosfamide, carboplatin,
etoposide, axitinib,
crizotinib, dasatinib,
erlotinib, everolimus,
imatinib, pazopanib,
ruxolitinib, sorafenib,
vandetanib, vemurafenib,
trastuzumab, pazopanib,
sorafenib
Precision
Medicine
Molecularly
Guided Therapy 90 up to 18 years
Seoul, Korea
(Samsung Medical
Center)
Active,
recruiting
NCT02639546
Safety and Pharmacokinetics of Cobimetinib
in Pediatric and Young Adult Participants
with Previously Treated Solid Tumors
(iMATRIXcobi)
Cobimetinib MEK
Molecularly
Targeted
Therapy
50 6 months to30 years Hoffmann-La Roche
Active,
recruiting
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Table 1. Cont.
NCT Number Title Drug Molecular Target TherapeuticClass
Study
Enrollment
Target
Eligibility
Age Range
Primary Site/Group
or Sponsor Status
NCT02641314
Metronomic Treatment in Children and
Adolescents with Recurrent or Progressive
High Risk Neuroblastoma
Propranolol, celecoxib,
cyclophosphamide,
vinblastine, etoposide
N/A SystemicChemotherapy 26 2–20 years
Cologne, Germany
(University of
Cologne)
Active,
recruiting
NCT02644460
Abemaciclib in Children with DIPG or
Recurrent/Refractory Solid Tumors
(AflacST1501)
Abemaciclib (LY2835219) CDK4/6
Molecularly
Targeted
Therapy
50 2–25 years
Atlanta, GA
(Children’s
Healthcare of Atlanta)
Active,
recruiting
NCT02650401
Study of RXDX-101 in Children with
Recurrent or Refractory Solid Tumors and
Primary CNS Tumors, With or Without TRK,
ROS1, or ALK Fusions
RXDX-101 (Entrectinib) TRK, ROS1, ALK MolecularlyGuided Therapy 190 2–22 years Hoffmann-La Roche
Active,
recruiting
NCT02650648
Humanized Anti-GD2 Antibody Hu3F8 and
Allogeneic Natural Killer Cells for High-Risk
Neuroblastoma
Hu3F8, cyclophosphamide,
NK cells, IL-2 GD2 Immunotherapy 36 any
New York, NY
(Memorial Sloan
Kettering Cancer
Center)
Active,
recruiting
NCT02743429
Phase II Study of Monoclonal Antibody
ch14.18/CHO Continuous Infusion in
Patients with Primary Refractory or Relapsed
Neuroblastoma
ch14.18/CHO GD2 Immunotherapy 40 1–21 years
Greifswald, Germany
(University Medicine
Greifswald)
Active,
recruiting
NCT02748135
A Two-Part Study of TB-403 in Pediatric
Subjects with Relapsed or Refractory
Medulloblastoma
TB-403 N/A SystemicChemotherapy 36
6 months to 18
years
Beat Childhood
Cancer (BCC)
Active,
recruiting
NCT02761915 A Cancer Research UK Trial of Anti-GD2T-cells (1RG-CART)
Anti-GD2 CAR-T cells,
cyclophosphamide,
fludarabine
GD2 Immunotherapy 27 over 1 year
London, UK
(University College
London)
Active,
recruiting
NCT02765243
Anti-GD2 4th Generation CART Cells
Targeting Refractory and/or Recurrent
Neuroblastoma
Anti-GD2 CAR-T cells GD2 Immunotherapy 30 1–14 years China (ZhujiangHospital)
Active,
recruiting
NCT02780128 Next Generation Personalized NeuroblastomaTherapy (NEPENTHE)
Ceritinib, trametinib,
HDM201, ribociclib
ALK, RAS-MAPK,
p53
Molecularly
Guided Therapy 105 1–21 years
Philadelphia, PA
(Children’s Hospital
of Philadelphia)
Active,
recruiting
NCT02813135
European Proof-of-Concept Therapeutic
Stratification Trial of Molecular Anomalies in
Relapsed or Refractory Tumors (ESMART)
Ribociclib, topotecan,
temozolomide, everolimus,
AZD1775, carboplatin,
olaparib, irinotecan,
AZD2014, nivolumab,
Vistusertib, selumetinib,
enasidenib, lirilumab
Precision
Medicine
Molecularly
Guided Therapy 397 up to 18 years
Villejuif, France
(Institut Gustave
Roussy)
Active,
recruiting
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Table 1. Cont.
NCT Number Title Drug Molecular Target TherapeuticClass
Study
Enrollment
Target
Eligibility
Age Range
Primary Site/Group
or Sponsor Status
NCT02909777
Trial of CUDC-907 in Children and Young
Adults with Relapsed or Refractory Solid
Tumors, CNS Tumors, or Lymphoma
CUDC-907 (fimepinostat) PI3K, HDAC
Molecularly
Targeted
Therapy
44 1–21 years
Boston, MA
(Dana-Farber Cancer
Institute)
Active,
recruiting
NCT02919046
Study Evaluating the Efficacy and Safety With
CAR-T for Relapsed or Refractory
Neuroblastoma in Children
Anti-GD2 CAR-T cells GD2 Immunotherapy 22 1–14 years China (NanjingChildren’s Hospital)
Active,
recruiting
NCT02982941 Enoblituzumab (MGA271) in Children withB7-H3-expressing Solid Tumors Enoblituzumab (MGA271) B7-H3 Immunotherapy 112 1–35 years MacroGenics
Active,
recruiting
NCT02998983 Racotumomab in Patients with High riskNeuroblastoma Racotumomab
N-glycolil (NGc)
GM3 (NGcGM3) Immunotherapy 39 1–12 years
Buenos Aires,
Argentina (Hospital
Universitario Austral)
Active,
recruiting
NCT03107988 Study of Lorlatinib (PF-06463922)
Lorlatinib,
cyclophosphamide,
topotecan
ALK, ROS1
Molecularly
Targeted
Therapy
40 1–90 years
New Approaches to
Neuroblastoma
Therapy (NANT)
Active,
recruiting
NCT03155620
Targeted Therapy Directed by Genetic Testing
in Treating Pediatric Patients with Relapsed or
Refractory Advanced Solid Tumors,
Non-Hodgkin Lymphomas, or Histiocytic
Disorders (Pediatric MATCH)
Palbociclib, selumetinib,
ensartinib, vemurafenib,
olaparib, larotrectinib,
LY3023414, erdafitinib
Precision
Medicine
Molecularly
Guided Therapy 49 1–21 years
Children’s Oncology
Group
Active,
recruiting
NCT03189706 Pilot Study of Chemoimmunotherapy forHigh-Risk Neuroblastoma
Hu3F8,
irinotecan/temozolomide,
GM-CSF
GD2 Immunotherapy 20 any
New York, NY
(Memorial Sloan
Kettering Cancer
Center)
Active,
recruiting
NCT03209869
Treatment of Relapsed or Refractory
Neuroblastoma with Expanded
Haploidentical NK Cells and Hu14.18-IL2
Hu14.18-IL2, NK cells GD2 Immunotherapy 6 7 months to21 years
Madison, WI
(University of
Wisconsin)
Active,
recruiting
NCT03236857
A Study of the Safety and Pharmacokinetics
of Venetoclax in Pediatric and Young Adult
Patients with Relapsed or Refractory
Malignancies
Venetoclax BCL-2
Molecularly
Targeted
Therapy
135 up to 25 years AbbVie Active,recruiting
NCT03242603
Immunotherapy of Neuroblastoma Patients
Using a Combination of Anti-GD2 and NK
Cells (NKEXPGD2)
Haploidentical NK cells,
ch14.18/CHO GD2 Immunotherapy 5
6 months to
25 years
Singapore (National
University Hospital)
Active,
recruiting
NCT03273712
Dosimetry-Guided, Peptide Receptor
Radiotherapy (PRRT) With
90Y-DOTA-tyr3-Octreotide (90Y-DOTATOC)
90Y-DOTA-tyr3-Octreotide
(90YDOTATOC)
SSTR SystemicRadiotherapy 20
6 months to
90 years
Iowa City, IA
(University of Iowa)
Active,
recruiting
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NCT Number Title Drug Molecular Target TherapeuticClass
Study
Enrollment
Target
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Age Range
Primary Site/Group
or Sponsor Status
NCT03275402
131I-burtomab Radioimmunotherapy for
Neuroblastoma Central Nervous
System/Leptomeningeal Metastases
131I-burtomab (8H9) B7-H3
Systemic
Radiotherapy 32 up to 18 years Y-mAbs Therapeutics
Active, not
yet
recruiting
NCT03294954
GD2 Specific CAR and Interleukin-15
Expressing Autologous NKT Cells to Treat
Children with Neuroblastoma (GINAKIT2)
NKT cells,
cyclophosphamide,
fludarabine
GD2 Immunotherapy 24 1–21 years Houston, TX (BaylorCollege of Medicine)
Active,
recruiting
NCT03332667 MIBG With Dinutuximab 131I-MIBG dinutuximab NET, GD2
Systemic
Radiotherapy
plus
Immunotherapy
24 1–30 years
New Approaches to
Neuroblastoma
Therapy (NANT)
Active, not
yet
recruiting
NCT03373097
Anti-GD2 CAR T Cells in Pediatric Patients
Affected by High Risk and/or
Relapsed/Refractory Neuroblastoma
Anti-GD2 CAR-T cells GD2 Immunotherapy 42 1–18 years
Italy (Bambino Gesù
Hospital and
Research Institute)
Active,
recruiting
NCT03434262
SJDAWN: St. Jude Children’s Research
Hospital Phase 1 Study Evaluating
Molecularly-Driven Doublet Therapies for
Children and Young Adults with Recurrent
Brain Tumors
Ribociclib, gemcitabine,
trametinib, sonidegib
Precision
Medicine
Molecularly
Guided Therapy 108 1–39 years
Memphis, TN (St.
Jude Children’s
Research Hospital)
Active,
recruiting
NCT03458728
Safety, Tolerability, Efficacy and
Pharmacokinetics of Copanlisib in
Pediatric Patients
Copanlisib (BAY806946) PI3K
Molecularly
Targeted
Therapy
130 6 months to21 years Bayer Pharma
Active,
recruiting
NCT03478462
Dose Escalation Study of CLR 131 in Children
and Adolescents with Relapsed or Refractory
Malignant Brain Cancer, Neuroblastoma,
Rhabdomyosarcoma, Ewings Sarcoma,
and Osteosarcoma
CLR 131 N/A SystemicRadiotherapy 30 2–21 years
Madison, WI
(University of
Wisconsin)
Active, not
yet
recruiting
NCT03507491
Nab-paclitaxel in Combination with
Gemcitabine for Pediatric Relapsed and
Refractory Solid Tumors
Nab-paclitaxel,
gemcitabine N/A
Systemic
Chemotherapy 24
6 months to
30 years
Atlanta, GA
(Children’s
Healthcare of Atlanta)
Active, not
yet
recruiting
NCT03561259
A Study of Therapeutic Iobenguane (131I) for
High-Risk Neuroblastoma at the Time of First
Relapse (OPTIMUM)
131I-MIBG NET
Systemic
Radiotherapy 65 over 1 year
Jubilant
DraxImage Inc.
Active,
recruiting
Molecularly Targeted Therapy—Targeted agent used in non-targeted fashion; Molecularly Guided Therapy—Targeted agent used in targeted patient population based on molecular
aberration or phenotype; NET—norepinephrine transporter; SSTR—somatostatin receptor; XRT—radiation therapy; ODC—ornithine decarboxylase, HIFU—high-intensity focused
ultrasound, HDAC—histone deacetylase; MIBG—meta-iodobenzylguanidine; CAR-T cells—chimeric antigen receptor T cells; ALK—anaplastic lymphoma kinase; NK cells—natural
killer cells.
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3.2. Aurora A Kinase
Additional efforts to identify novel targets in neuroblastoma tumors have identified a critical role
for mitotic spindle regulation in neuroblastoma pathogenesis, suggesting that regulators of the mitotic
spindle represent potential therapeutic targets. Aurora A kinase represents one such potential target
and is essential for appropriate completion of mitosis through regulation of the mitotic checkpoint
complex [61]. Aberrant overexpression of aurora A kinase leads to tumor cell resistance to apoptosis
and genomic instability [62], and, in neuroblastoma tumors, aurora A kinase expression correlates with
high-risk disease and advanced tumor stage [63,64]. Inhibitors of aurora A kinase were shown to block
neuroblastoma cell growth and to increase neuroblastoma cell responses to chemotherapy [63], and,
in initial phase I trials, children with relapsed neuroblastoma treated with the aurora A kinase inhibitor
MLN8237 (alisertib), both alone and in combination with irinotecan and temozolomide, demonstrated
clinical responses [65,66]. More recent studies have identified polo-like kinase 4 (PLK4) as a potential
target in neuroblastoma tumor cells [67], further implicating the process of mitotic spindle regulation
in neuroblastoma pathogenesis and suggesting that children with relapsed neuroblastoma will benefit
from the use of inhibitors of aurora A kinase and PLK4 for treatment.
3.3. Ornithine Decarboxylase (ODC1)
Ornithine decarboxylase (ODC1), the rate-limiting enzyme in polyamine synthesis, is frequently
deregulated in neuroblastoma tumors [68,69] and represents another potential therapeutic target.
ODC inhibitors, such as difluoromethylornithine (DFMO), have been shown to be effective in
neuroblastoma preclinical models [70–72] and, although single-agent DFMO did not demonstrate
efficacy in children with relapsed neuroblastoma in a recent phase I clinical trial [73], more recent
studies have demonstrated that extended maintenance therapy with DFMO for children with
neuroblastoma in second remission results in 2-year overall and event-free survival rates of 54%
and 84% [74], respectively, suggesting that ODC1 inhibition is an effective strategy for prolonging
survival in these patients. The efficacy of DFMO in combination with other anticancer agents,
including cyclophosphamide, topotecan, and celecoxib (NCT02030964) and the proteasome inhibitor
bortezomib (NCT02139397), is also currently being evaluated in clinical trials for children with relapsed
neuroblastoma, in the hopes of observing synergistic efficacy.
3.4. PI3K/AKT/mTOR
Further studies in neuroblastoma preclinical models have confirmed a role for the PI-3
kinase/AKT/mTOR pathway in neuroblastoma pathogenesis. SF1126 is a pan-PI-3 kinase inhibitor
that has been demonstrated to be effective against neuroblastoma in preclinical models [75], suggesting
this pathway represents a therapeutic target in neuroblastoma, and clinical trials have been opened
to test the safety and tolerability of SF1126 in children with relapsed neuroblastoma (NCT02337309).
The AKT inhibitor perifosine has been tested in multiple phase I clinical trials, with 1 complete response
and 8 of 27 children with relapsed neuroblastoma demonstrating prolonged stable disease in one
phase I study [76], and response rates and disease control rates of 9% and 55% in 11 children with
neuroblastoma with measurable disease [77]. Early studies also determined that mTOR inhibitors were
effective in neuroblastoma models [78,79], and one of two patients with relapsed neuroblastoma had a
CR in initial phase I studies with the mTOR inhibitor temsirolimus [80]. A follow-up phase II study
did not meet predetermined efficacy criteria, but 7 of 19 patients with neuroblastoma demonstrated
clinical benefit (1 PR, 6 SD) [81], and 2 patients with relapsed neuroblastoma had prolonged stable
disease in response to the combination of vinblastine and sirolimus [82], suggesting that a subset of
patients may benefit from the inhibition of this pathway.
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3.5. Epigenetic Modifications
Epigenetic modifications to DNA involve heritable genomic modifications that are not due to
changes in the DNA sequence, including DNA and histone methylation and histone acetylation. These
modifications influence chromatin structure and play a key role in regulating gene expression [83].
Epigenetic regulation of gene expression is critical for both normal development and maintenance of
tissue-specific gene expression, but aberrant epigenetic mechanisms can contribute to the malignant
process, and epigenetic changes contribute to the genomic instability that is a hallmark of cancer [84].
The epigenomic landscape has been shown to contribute to neuroblastoma pathogenesis, leading to
early phase clinical trials investigating the safety and efficacy of epigenetic agents [85–87], including
drugs that target epigenetic writers, such as DNA methyltransferases, as well as epigenetic erasers,
such as histone deacetylases [88]. An early phase I study using the demethylating agent decitabine
combined with chemotherapy resulted in prolonged stable disease in 5 of 14 patients with relapsed
neuroblastoma, although the doses of decitabine were limited due to toxicity [89]. A subsequent study
of the combination of the HDAC inhibitor vorinostat combined with bortezomib did not show any
responses in the three patients with relapsed neuroblastoma enrolled [90], and further combination
studies using vorinostat in children with neuroblastoma are ongoing (NCT02035137, NCT02559778) to
identify patient populations that may have improved responses.
Modulation of the epigenetic readers—proteins that recognize and bind to epigenetic chromatin
modifications to modulate gene transcription—has recently emerged as a therapeutic strategy for
anticancer treatment. Bromodomain and extraterminal domain (BET) proteins are epigenetic readers
that regulate gene transcription, and BET inhibitors preferentially bind to super-enhancers—regions
of DNA comprising multiple enhancers occupied by transcription factors and regulators of gene
transcription that control the expression of genes critical for cell identity, growth, and survival [91].
Further studies have identified critical roles for chromatin structure and super-enhancers in
neuroblastoma [92], and BET inhibitors have been shown to be effective against neuroblastoma
via targeting of MYCN gene expression [93,94]. A number of BET inhibitors are in clinical development
and early phase clinical trials, including a novel dual PI3K–BRD4 inhibitor that was effective in
neuroblastoma preclinical models [95]. BET inhibitors therefore represent an exciting new class of
therapeutic agents for children with relapsed neuroblastoma.
3.6. Reactive Oxygen Species (ROS)
Reactive oxygen species (ROS) have been shown to impact a variety of critical intracellular
signaling pathways, and prior studies have identified a role for ROS in cancer pathogenesis [96].
However, the role of ROS in neuroblastoma tumors is less clear. Nifurtimox is a nitrofuran derivative
that has been used for decades as a primary treatment for Chagas’ disease, a parasitic infection caused
by the protozoan Trypanosoma cruzi [97,98]. Nifurtimox was shown to inhibit neuroblastoma cell growth
both in vitro and in vivo in preclinical studies, most likely via inhibition of ROS production [99,100],
and in early phase clinical trials, patients treated with nifurtimox both as a single agent and in
combination with chemotherapy demonstrated responses [101], leading to an ongoing national phase
II trial (NCT00601003). A separate study investigating the combination of melphalan with buthionine
sulfoximine (BSO) resulted in 6 of 31 patients with relapsed neuroblastoma demonstrating objective
responses (5PR, 1MR) [102], and the recent demonstration of synergy between nifurtimox and BSO in
other solid tumor models [100] suggests that further testing of the combination of nifurtimox and BSO
in neuroblastoma preclinical models is warranted.
3.7. Retinoids
Retinoid therapy has been shown to increase EFS rates when used as a component of maintenance
therapy for high-risk neuroblastoma [103], and studies have demonstrated potential synergy of
retinoids with epigenetic modifying agents [104,105]. An initial phase I study of the combination of
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the HDAC inhibitor vorinostat with 13-cis-retinoic acid had one patient with neuroblastoma who had
a CR following treatment [106], and a more recent phase I study of vorinostat in combination with
13-cis-retinoic acid for children with relapsed neuroblastoma found no objective responses, but 11 of 29
evaluable patients had SD, with 7 of the 11 receiving at least 11 cycles of therapy [107]. Additionally,
the RET tyrosine kinase, which is primarily expressed in cells and tissues derived from the neural crest,
has been shown to be required for maturation of the peripheral nervous system, and RET was further
shown to be required for neuroblastoma differentiation induced by retinoic acid [108]. RET inhibition
has been found to be effective in in vitro and in vivo preclinical models of neuroblastoma [109–111],
and a recently opened clinical trial (NCT03611595) will evaluate the efficacy of the combination of RET
inhibition and retinoid therapy in children with neuroblastoma and other solid tumors.
3.8. Molecularly Guided Therapy
With the rapid advances in our understanding of the biology of cancer, the use of molecular tumor
profiling to develop individualized treatment plans is increasingly employed for many adults with a
variety of cancers [112]. Although the efficacy of this strategy in children with cancer remains mostly
unknown, recently completed clinical trials have evaluated the potential feasibility and efficacy of
utilizing molecular and genetic tumor profiling to develop personalized therapy for children with
recurrent neuroblastoma. An initial pilot study demonstrated the feasibility of obtaining tumor
biopsies from children with relapsed neuroblastoma and then performing DNA sequencing and
RNA expression profiling on the relapsed tumor sample, which allowed investigators to generate
individualized patient treatment plans in less than 12 days [113]. A follow-up multi-institutional
phase I trial employing the same strategy showed that 64% of patients achieved either partial or
complete response or disease stabilization for at least one cycle of therapy, with a 7% overall response
rate and a progression-free survival time of 59 days [114]. A subsequent single-institution study
also demonstrated that the utilization of DNA sequencing data from relapsed tumors to generate
prospective treatment plans for children with neuroblastoma was feasible, with nearly half of patients
enrolled in the study having potentially actionable genetic findings. Tumor DNA sequencing also led
to changes in patient treatment and to genetic counseling for relatives and families of patients found to
be at risk of other hereditary disorders [115]. Additional concurrent studies have also demonstrated
the feasibility of using genomic data [116] and more comprehensive molecular profiling [117] to
identify potential therapeutic targets in children with high-risk, relapsed, or refractory cancers. These
results all clearly demonstrate the feasibility of employing molecular profiling to guide individualized
treatment strategies for children with neuroblastoma. However, the lack of control groups in these
and other studies has limited the ability to assess whether this individualized molecularly targeted
treatment resulted in better clinical outcomes for patients when compared with outcomes using
standard non-targeted treatment or molecularly targeted agents in an untargeted fashion. Clinical
trials to further evaluate the efficacy of molecularly guided, individualized therapy in children with
relapsed neuroblastoma and other pediatric solid tumors are currently being developed or are ongoing
(NCT02162732, NCT02520713, NCT02638428, NCT03155620, NCT03434262).
4. Immunotherapy
Although a number of recent studies have demonstrated the efficacy of various forms of
immunotherapy against neuroblastoma and other pediatric solid tumors, the role of immunotherapy
in the treatment of patients with relapsed or refractory neuroblastoma is the focus of numerous prior
and ongoing studies. Early studies demonstrated promising results for anti-GD2 antibody therapy
in children with relapsed neuroblastoma [118–120], leading to the evaluation of the efficacy of the
chimeric anti-GD2 antibody ch14.18 (dinutuximab) as a component of maintenance therapy for children
with high-risk neuroblastoma [121]. Additional studies demonstrated significant efficacy of the mouse
anti-GD2 antibody 3F8 in children with relapsed neuroblastoma, with 33% 5-year progression-free
survival (PFS) in patients who were treated for relapsed neuroblastoma and achieved either a CR or
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very good partial response (VGPR) and were then treated with 3F8 plus GM-CSF and 13-cis-retinoic
acid [10].
4.1. Antibody Immunotherapy
Further studies have attempted to expand the use of anti-GD2 antibody therapy in children
with relapsed neuroblastoma by employing combinations with other therapies, in addition to
the development and evaluation of modified forms of the antibodies themselves. A recent trial
combining irinotecan and temozolomide with the anti-GD2 antibody dinutuximab demonstrated
promising results, with 9 objective responses (including 5 with CR) among 17 patients receiving the
combination [122]. Preliminary data from a follow-up study through the Children’s Oncology Group
included data from 53 total eligible patients, with 21 patients (40%) experiencing objective responses,
including 11 with CR [123], confirming this combination as a treatment regimen to be considered
for children with neuroblastoma at the time of initial relapse. A phase I trial using a humanized
version of the ch14.18 antibody with a mutation engineered to reduce side effects (hu14.18K322A)
found 6 of 39 enrolled patients had either PR or CR, with 9 additional patients having prolonged
SD [124]. A humanized version of the anti-GD2 antibody 3F8 also recently underwent phase I
testing, with increased PFS among patients with a higher anti-GD2 antibody titer and reduced overall
immunogenicity [125]. In a separate study, 39 patients with recurrent neuroblastoma were treated
with the Hu14.18-IL-2 immunocytokine—a fusion protein combining the humanized 14.18 anti-GD2
antibody with IL-2. Of 13 patients with measurable soft tissue neuroblastoma tumors treated with
Hu14.18-IL-2, no objective responses were seen, but in those with only MIBG-avid disease or with
disease limited to the bone marrow, there were 5 complete responses out of 23 patients [126], suggesting
that patients with minimal residual disease are most likely to benefit from this therapy. Further
analyses have also shown that mismatches among natural killer (NK) cell KIR/KIR-ligand genotypes
and polymorphisms in the Fcγ receptor are also associated with improved responses to anti-GD2
immunotherapy [127,128], suggesting that further strategies for improvement in antibody design and
patient selection may result in improved outcomes.
One of the drawbacks to antibody therapy for neuroblastoma is that neuroblastoma tumors
use a variety of strategies to evade the host immune response, including downregulation or weak
immunogenicity of target antigens and creation of an immune-suppressive tumor environment. With the
significant side effects experienced by patients receiving anti-GD2 antibody immunotherapy and with
the challenges of antibody administration to patients, a number of alternative immunotherapy strategies
are currently under investigation. Immunomodulatory checkpoint inhibitors, such as ipilimumab
and nivolumab, have been employed in adult cancers to overcome the immune-suppressive tumor
microenvironment. Although ipilimumab was well tolerated in a phase I study for children with
relapsed solid tumors, only one patient enrolled in the study had neuroblastoma, and no objective
tumor regressions were observed [129]. Ongoing studies evaluating the efficacy of nivolumab with and
without added ipilimumab (NCT02304458), with the PD-1 inhibitor pembrolizumab (NCT02332668),
and with the anti-PD-L1 antibody atezolizumab (NCT02541604) will hopefully provide more insight
to their potential efficacy in children with relapsed neuroblastoma.
Anticancer vaccines have been tested in clinical trials for a number of different tumor types, and
an early clinical trial of anti-neuroblastoma vaccine therapy showed the ability to induce an antitumor
immune response, although the immune response was insufficient to induce tumor responses or
prevent disease progression [130]. A subsequent trial using decitabine combined with a dendritic
cell vaccine targeting MAGE-A1, MAGE-A3, and NY-ESO-1 resulted in 1 complete response out of
10 evaluable patients [131], and ongoing cancer vaccine trials include one trial exploring the efficacy
of a vaccine using the GD2L and GD3L antigens linked to KLH and administered with the adjuvant
OPT-821 and beta-glucan (NCT00911560).
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4.2. Cell-Based Immunotherapy
CD8+ T lymphocytes play a key role in cell-mediated immunity and, when infused as a form
of immunotherapy, offer the advantage of direct tumor targeting that can avoid or overcome the
tumor cell strategies to evade the host’s own immune system. Cell therapy with CD8+ T cells has
been employed in early phase clinical trials for children with relapsed neuroblastoma, with some
notable successes. EBV-specific T lymphocytes engineered to express a chimeric antigen receptor
(CAR) directed against GD2 resulted in 3 patients with complete responses out of 11 total treated
patients with active disease [132,133]. CAR-T cell persistence was associated with improved responses
and longer times to progression in these patients. Next-generation CAR-T cells, using constructs with
modified costimulatory domains to regulate T cell activation, are currently being developed [134],
and a number of national and international clinical trials are currently ongoing to further explore the
efficacy of novel CAR-T cell products targeted against GD2 in children with relapsed neuroblastoma
(NCT02239861, NCT02761915, NCT02765243, NCT02919046, NCT03373097). Other trials using CAR-T
cells targeted against other cell surface markers, such as CD171, are also currently undergoing testing
in clinical trials for children with neuroblastoma (NCT02311621).
Natural killer (NK) cells are another type of cytotoxic lymphocyte that can act in an
MHC-unrestricted fashion to target cancer cells. Cell-based immunotherapy using NK cells for children
with relapsed neuroblastoma has also been explored, particularly after the report of a child with
relapsed neuroblastoma who received haploidentical donor NK cells combined with temozolomide,
topotecan, and IL-2 and had a complete response [135]. Ongoing clinical trials are evaluating the
efficacy of ex vivo expanded haploidentical NK cells infused after haploidentical allogeneic stem cell
transplants for children with solid tumors, including neuroblastoma (NCT02100891), and a recently
opened clinical trial will explore the efficacy of expanded autologous natural killer T (NKT) cells
engineered to express the GD2-specific CAR and IL-15 (NCT03294954). A trial using the hu14.18K322A
anti-GD2 antibody combined with chemotherapy, cytokines, and haploidentical NK cells demonstrated
a 61% response rate in 13 heavily pretreated patients, with 4 complete responses, 1 very good partial
response, and 3 partial responses, in addition to 5 patients with stable disease and 10 of the 13 patients
(77%) surviving for at least 1 year [136], demonstrating the efficacy of treatment regimens that combine
multiple immunotherapeutic strategies. A number of other trials are investigating the combination
of haploidentical NK cells combined with anti-GD2 antibody therapy, including NK cells combined
with dinutuxumab and lenalidomide (NCT02573896), humanized 3F8, cyclophosphamide, and IL-2
(NCT02650648), the immunocytokine Hu14.18-IL-2 (NCT03209869); and ch14.18/CHO (NCT03242603).
Further studies of this approach are clearly warranted in patients with relapsed neuroblastoma.
5. Summary
The treatment of children with relapsed and refractory neuroblastoma remains a challenge,
and the outcomes for these children remain poor despite decades of effort by clinicians and scientists.
Recent advances in our understanding of the biology of neuroblastoma and of novel strategies to
target tumor-specific pathways and antigens have led to a dramatic increase in the number of available
treatment options for these patients and give hope that, in the future, novel treatment regimens will
increase the responses of tumors to upfront therapy, limit the overall chances of relapse, and, in those
hopefully rare cases of relapse, provide safe and effective therapies to eradicate neuroblastoma tumors.
Continued development of novel therapies and therapeutic regimens directed against biologically
relevant pathways and of novel approaches to harness the therapeutic potential of the innate immune
system will provide new treatment strategies to improve the outcomes for these children.
The relative paucity of therapeutically actionable gene mutations has limited the development
of individualized treatment regimens for children with neuroblastoma, but as we obtain increased
knowledge of other mechanisms of altered gene and protein expression and aberrant function in
neuroblastoma tumors, we are likely to identify additional relevant therapeutic targets. Studies to
further delineate the critical genetic and proteomic aberrations that either contribute to neuroblastoma
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pathogenesis or influence neuroblastoma tumor responses to treatment are ongoing, and these
aberrations will hopefully lead to the development of individualized patient treatment regimens
and also hopefully serve as targets for future drug development. A number of novel therapies
directed against recently identified molecular targets are currently being evaluated both in preclinical
models and in early phase clinical trials, and established national and international collaborations and
cooperative groups will provide opportunities to evaluate these new treatments in carefully controlled
clinical trials, leading to more precise and effective therapeutic regimens.
The future holds promise for making considerable advances in our treatment of relapsed
neuroblastoma, although continued difficulties in the management of metastatic, widespread relapse
and in specific cases of isolated relapses, such as relapse in the CNS, represent ongoing challenges for
the future. Although recent results need to be validated in future trials, these results do suggest that we
should reconsider our treatment goals for many patients, particularly with the successes of treatments
using extended maintenance therapy and immunotherapy for those patients who can achieve disease
remission after relapse. Future treatment decisions need to be made based on not only the underlying
diagnosis and clinical features of the patient, but also on the molecular features of the tumor itself and
the feasibility and availability of tumor-specific treatment. The goals of future clinical and translational
research should include identification and validation of the most effective treatment combinations,
determination of the most appropriate patients and situations for use of effective therapies, and further
delineation of the molecular subgroups of recurrent and refractory neuroblastoma to tailor treatment
regimens to the patient populations most likely to benefit. Continued attempts to both develop novel
therapeutic agents with efficacy against neuroblastoma tumors and to identify critical intracellular
signaling pathways relevant for neuroblastoma pathogenesis and treatment resistance are underway,
potentially leading to both individualized and improved treatment and to improved outcomes for
children with relapsed and refractory neuroblastoma.
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